SBIR TOPIC 259: QUANTITATIVE TISSUE IMAGING FOR CLINICAL DIAGNOSIS AND PROGNOSIS

尽管我们对癌症的了解有了进步，新的治疗方法也在发展，但癌症仍然 美国的第二大杀手，许多癌症的死亡率相对保持不变 几十年。前列腺癌是最常见的癌症，也是癌症相关死亡的第二大原因。 在西方国家的男性中。迫切需要确定可靠的新生物标志物，以 帮助及早发现前列腺癌，最重要的是，确定前列腺癌的风险 初治后复发，如前列腺切除术。目前IHE的主要治疗方式是新的 确诊的前列腺癌仍然是根治性前列腺切除术。根治性前列腺切除术提供了一种极好的 器官受限疾病的结局。然而，15%-20%或更多的手术患者最终 复发表明存在残留病、局部侵袭和/或转移沉积 在手术时。我们正在开发一种新的测试方法，使用新的方法来识别细胞特异性 可以在诊断时应用的生物标记物，以确定肿瘤是否有潜力！至 术后复发。一种能够区分惰性和攻击性的临床测试的开发 诊断时的疾病类型将提供关键的指导。首先，这些信息将提供 关于谁需要治疗的指导，从而提供了避免手术和相关的 对于那些复发风险较高的患者，其发病率较高。其次，这些信息还将提供指导 至于谁可以从术后或立即辅助治疗中受益。

Despite advances in our understanding of cancer and the development of new therapeutics, cancer remains the number two killer in the US with mortality rates of many cancers remaining relatively unchanged for decades. Prostate cancer is the most common cancer and second leading cause of cancer-related death among males of Western countries. There is a critical unmet need to identify reliable novel biomarkers to assist in early detection of prostate cancer, and, most critically, to determine risk of prostate cancer recurrence following initial lherapy such as prostatectomy. Currently Ihe major treatment modality for newly diagnosed prostate cancer remains radical prostatectomy. Radical prostatectomy provides an excellent outcome for organ-confined disease. However, 15%-20% or more of all surgical patients ultimately experience recurrence indicating the presence of residual disease, local invasion andlor metastatic deposits at the time of surgery .We are developing a new test using novel methods that identify cell-specific biomarkers that can be applied at the time of diagnosis to determine whether the tumor has the potentia! to recur after surgery. The development of a clinical test capable of distinguishing indolent and aggressive forms of the disease at the time of diagnosis wi ll provide crucial guidance. First, this information will provide guidance as to who needs treatment thereby providing the option of avoiding surgery and the associated morbidity for those patients with a high risk of recurrence. Second, this information will also provide guidance as to who may profit from postsurgery or immediate adjuvant therapy.